Search - tctmd.com

Displaying 161 - 180 of 284

Sort: Relevancy | Date

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Advent of High-Sensitivity Troponin Tests in Sweden Leads to Only Small Uptick in MI Diagnoses

Caitlin E. Cox

June 06, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Michael O'Riordan

April 16, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Daily News

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

L.A. McKeown

February 15, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

L.A. McKeown

December 01, 2017

News Conference News AHA 2017

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

Yael L. Maxwell

November 27, 2017

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Caitlin E. Cox

November 14, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

L.A. McKeown

September 25, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Daily News

More Liberal Definition of Type 2 MI May Misclassify Some Patients

Todd Neale

September 20, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Conference News ESC 2017

Acute MI Mortality Has Dropped to Very Low Levels in France

Todd Neale

September 08, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Advertisement

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Advent of High-Sensitivity Troponin Tests in Sweden Leads to Only Small Uptick in MI Diagnoses

Alirocumab Price Slashed in Deal With Express Scripts

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

More Liberal Definition of Type 2 MI May Misclassify Some Patients

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Acute MI Mortality Has Dropped to Very Low Levels in France

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content